扶正化瘀（FZHY）已完成II期临床试验治疗肝纤维化

StephenW

Note: FZHY is also being used for Hepatitis B
扶正化瘀（FZHY）已完成II期临床试验治疗肝纤维化的慢性丙型肝炎患者

SHANGHAI, CHINA--(Marketwired - Nov 5, 2013) - Shanghai Sundise Traditional Chinese Medicine Co. Ltd today released its multi-center, double-blinded, placebo-controlled clinical phase II trial results at a satellite symposium during the 2013 annual meeting of American Association for Study of Liver Diseases (AASLD®). The results indicate that in chronic hepatitis C patients with moderate to severe fibrosis Fuzheng Huayu tablet (FZHY) is safe, well tolerated and tended to stabilize and improve liver fibrosis, making FZHY the first traditional Chinese medicine compound to complete such clinical studies in the treatment of liver diseases.

Hepatitis C is the major cause of liver fibrosis, cirrhosis and ultimately hepatocellular carcinoma (HCC) in the US. Newly approved direct-acting antiviral agents may effectively clear hepatitis C virus. However, the effects on underline liver fibrosis and cirrhosis remain to be seen. Currently, there is no FDA approved anti-fibrosis therapy. FZHY is a botanical compound approved in China for liver fibrosis caused by hepatitis B virus infection. This is the first clinical phase II trial of FZHY as botanical drug to assess the safety, tolerability, and efficacy on fibrosis in HCV patients who have been previously failed the anti-viral therapies, cannot receive or refused Interferon based therapy. The trial was initiated in 2010 to evaluate FZHY with treatment protocol for one year and pre- and post-treatment liver biopsy assessments. The trial was funded by Shanghai Sundise Traditional Chinese Medicine Co. Ltd, with eight US medical institutions and a team of world-famous liver specialists working together. Detailed trial information is available at www.clinicaltrials.gov (Identifier: NCT00854087).

Read more: http://www.digitaljournal.com/pr/1568024#ixzz2ju7mEYUp

重肝过后

谢谢！
我在扶正化淤的官方微博询问，结果惹了一肚子气。
tended to stabilize and improve liver fibrosis,这个tend to你怎么理解？

StephenW

回复 重肝过后 的帖子

"Tend"趋向,  必须等待第3阶段的疗效

重肝过后

StephenW 发表于 2013-11-7 18:50
回复 重肝过后 的帖子

"Tend"趋向,  必须等待第3阶段的疗效

就是说依然没有统计学认可的具有显著差异性的证据？还是二期本来就不做这种事情，必须三期？

StephenW

回复 重肝过后 的帖子

assess the safety, tolerability, and efficacy是的，评估安全性，耐受性和疗效 ,
很难证明纤维化改善

重肝过后

回复 StephenW 的帖子

谢了。没法等了，既然安全性还可以，就吃吧

远安

重肝过后 发表于 2013-11-7 19:30
回复 StephenW 的帖子

谢了。没法等了，既然安全性还可以，就吃吧

扶正化瘀这玩意即使安全也增加肝脏负担，还是不吃为好！省点银子吃恩替吧。

MP4

远安 发表于 2013-11-11 22:12
扶正化瘀这玩意即使安全也增加肝脏负担，还是不吃为好！省点银子吃恩替吧。 ...

国内已经证实有效。

远安

MP4 发表于 2013-11-15 13:03
国内已经证实有效。

你说的不错，就和鳖甲软肝片一样，专家们都说在国内已经证实有效，而且有大效，糊弄了、耽误了多少硬人啊！退一步说即便有效、它也治不了乙肝病毒，“庆父不死，鲁难未已”，这么浅显的道理，那些自卖自夸的真的不懂吗。

MP4

远安 发表于 2013-11-16 07:17
你说的不错，就和鳖甲软肝片一样，专家们都说在国内已经证实有效，而且有大效，糊弄了、耽误了多少硬人啊 ...

专家说有效，没说特效。
若然有特效，抗病毒的确是可有可无的。
你说的糊弄不足为信的。